UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phase Ib/II Trial of NC-6004 (Nanoparticle Cisplatin) Plus Gemcitabine in Patients with Advanced Solid Tumors

Clinical cancer research, 2018-01, Vol.24 (1), p.43-51

2018

Volltextzugriff (PDF)

Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma a randomized, double-blind, multicenter, comparative trial

Cancer, 2003-10, Vol.98 (8), p.1735-1744

2003

Volltextzugriff (PDF)

Zoledronic Acid Versus Placebo in the Treatment of Skeletal Metastases in Patients With Lung Cancer and Other Solid Tumors: A Phase III, Double-Blind, Randomized Trial—The Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group

Journal of clinical oncology, 2003-08, Vol.21 (16), p.3150-3157

2003

Volltextzugriff (PDF)

Challenges in the development of an autologous heat shock protein based anti-tumor vaccine

Human vaccines & immunotherapeutics, 2012-08, Vol.8 (8), p.1152-1155

2012

Volltextzugriff (PDF)

Efficacy of Pamidronate in Reducing Skeletal Complications in Patients with Breast Cancer and Lytic Bone Metastases

The New England journal of medicine, 1996-12, Vol.335 (24), p.1785-1792

1996

Volltextzugriff (PDF)

EBV-Related Lymphoproliferative Disease Complicating Therapy with the Anti-CD2 Monoclonal Antibody, Siplizumab, in Patients with T-Cell Malignancies

Clinical cancer research, 2009-04, Vol.15 (7), p.2514-2522

2009

Volltextzugriff (PDF)

Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

The New England journal of medicine, 1996-02, Vol.334 (8), p.488-493

1996

Volltextzugriff (PDF)

Pamidronate Reduces Skeletal Morbidity in Women With Advanced Breast Cancer and Lytic Bone Lesions: A Randomized, Placebo-Controlled Trial

Journal of clinical oncology, 1999-03, Vol.17 (3), p.846-854

1999

Volltextzugriff (PDF)

Alternative statistical strategies for biosimilar drug development

GaBI Journal, 2014-03, Vol.3 (1), p.13-20

2014

Volltextzugriff (PDF)

Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: A randomized, phase III, double-blind, placebo-controlled trial

Cancer, 2004-06, Vol.100 (12), p.2613-2621

2004

Volltextzugriff (PDF)

Managing combination immunotherapy trials from a contract research organization's (CRO's) perspective

Journal of clinical oncology, 2019-03, Vol.37 (8_suppl), p.19-19

2019

Volltextzugriff (PDF)

Implications of biosimilar development: demonstrating biosimilarity is highly dependent on the unique characteristics of the product

Applied clinical trials, 2012-09, Vol.21 (9), p.50

Reitsma, Dirk

2012

Volltextzugriff (PDF)

Implications of Biosimilar Development

Applied clinical trials, 2012-09, Vol.21 (9), p.50

Reitsma, Dirk

2012

Volltextzugriff (PDF)

Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases long term follow-up of two randomized, placebo-controlled trials

Cancer, 2000-03, Vol.88 (5), p.1082-1090

2000

Volltextzugriff (PDF)

Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial

The cancer journal (Sudbury, Mass.), 2001-09, Vol.7 (5), p.377

2001

Volltextzugriff (PDF)

Adult participation in oncology clinical trials by indication, race, and age

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.e17586-e17586

2013

Volltextzugriff (PDF)

Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate

Journal of clinical oncology, 1998-06, Vol.16 (6), p.2038-2044

1998

Volltextzugriff (PDF)

Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events

Journal of clinical oncology, 1998-02, Vol.16 (2), p.593-602

1998

Volltextzugriff (PDF)

Highlighting the challenge of delayed overall survival (OS) curve separation in immunotherapy clinical trials

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.3009-3009

2013

Volltextzugriff (PDF)

HER2+ gastric cancer patient demographics and implications for clinical trial enrollment

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.e12526-e12526

2014

Volltextzugriff (PDF)

Uptake of BRAF and ALK mutation screening versus HER2 overexpression testing

Journal of clinical oncology, 2012-10, Vol.30 (30_suppl), p.101-101

2012

Volltextzugriff (PDF)

Improving oncology trials through adaptive designs: how the practical application of these methods can help overcome the complex demands of cancer trials

Applied clinical trials, 2015-04, p.30

2015

Volltextzugriff (PDF)

Improving Oncology Trials Through Adaptive Designs

Applied clinical trials, 2015-04, Vol.24 (4/5), p.30

2015

Volltextzugriff (PDF)

The New Bisphosphonate, Zometa® (Zoledronic Acid), Decreases Skeletal Complications in Both Osteolytic and Osteoblastic Lesions: A Comparison to Pamidronate

Cancer investigation, 2002, Vol.20 (S2), p.45-54

2002

Volltextzugriff (PDF)

Quantitation of ineterferon-induced Mx protein in whole blood lysates by an immunochemiluminsescent assay: elimination of protease activity of cell lysates in toto

Journal of immunological methods, 1994-11, Vol.176 (1), p.79-91

1994

Volltextzugriff (PDF)

1 – 25 von 57

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(55)
Mit Volltextzugriff
(48)

Publikationsform

Artikel
(56)
Buchkapitel
(1)

Sprache

Englisch
(57)

Erscheinungsjahr

n.n

Thema

Science & Technology
(35)
Life Sciences & Biomedicine
(34)
Humans
(27)
Biological And Medical Sciences
(19)
Female
(19)
Male
(18)
Medical Sciences
(18)
Middle Aged
(18)
Aged
(12)
Oncology
(12)
Pharmacology. Drug Treatments
(10)
General & Internal Medicine
(9)
Adult
(6)
Bone Neoplasms - Secondary
(6)
Diphosphonates - Therapeutic Use
(6)
Medicine, General & Internal
(6)
Patients
(6)
Peritonitis - Surgery
(6)
Surgery
(6)
Antineoplastic Agents - Therapeutic Use
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase Ib/II Trial of NC-6004 (Nanoparticle Cisplatin) Plus Gemcitabine in Patients with Advanced Solid Tumors

Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma a randomized, double-blind, multicenter, comparative trial

Zoledronic Acid Versus Placebo in the Treatment of Skeletal Metastases in Patients With Lung Cancer and Other Solid Tumors: A Phase III, Double-Blind, Randomized Trial—The Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group

Challenges in the development of an autologous heat shock protein based anti-tumor vaccine

Efficacy of Pamidronate in Reducing Skeletal Complications in Patients with Breast Cancer and Lytic Bone Metastases

EBV-Related Lymphoproliferative Disease Complicating Therapy with the Anti-CD2 Monoclonal Antibody, Siplizumab, in Patients with T-Cell Malignancies

Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

Pamidronate Reduces Skeletal Morbidity in Women With Advanced Breast Cancer and Lytic Bone Lesions: A Randomized, Placebo-Controlled Trial

Alternative statistical strategies for biosimilar drug development

Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: A randomized, phase III, double-blind, placebo-controlled trial

Managing combination immunotherapy trials from a contract research organization's (CRO's) perspective

Implications of biosimilar development: demonstrating biosimilarity is highly dependent on the unique characteristics of the product

Implications of Biosimilar Development

Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases long term follow-up of two randomized, placebo-controlled trials

Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial

Adult participation in oncology clinical trials by indication, race, and age

Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate

Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events

Highlighting the challenge of delayed overall survival (OS) curve separation in immunotherapy clinical trials

HER2+ gastric cancer patient demographics and implications for clinical trial enrollment

Uptake of BRAF and ALK mutation screening versus HER2 overexpression testing

Improving oncology trials through adaptive designs: how the practical application of these methods can help overcome the complex demands of cancer trials

Improving Oncology Trials Through Adaptive Designs

The New Bisphosphonate, Zometa® (Zoledronic Acid), Decreases Skeletal Complications in Both Osteolytic and Osteoblastic Lesions: A Comparison to Pamidronate

Quantitation of ineterferon-induced Mx protein in whole blood lysates by an immunochemiluminsescent assay: elimination of protease activity of cell lysates in toto

Suchergebnisse filtern